Rhythm Pharmaceuticals’ setmelanotide receives US FDA approval to treat patients living with acquired hypothalamic obesity: Boston Saturday, March 21, 2026, 18:00 Hrs [IST] Rhyt ...

研究结果表明，采用多学科协作、标准化方案的诊疗模式，有助于改善下丘脑错构瘤患者的预后。对于尚未形成共识的领域，如特异性内分泌检查项目、部分干预措施的实施时机等，仍需开展进一步研究并建立行业标准。

First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and ...

Rhythm Pharmaceuticals is switching up the tempo for its melanocortin-4 receptor (MC4R) agonist Imcivree. | The new FDA nod makes Rhythm Pharma's Imcivree the first approved drug for acquired ...

The melanocortin 4 receptor agonist setmelanotide is now FDA approved for weight management in adults and children with ...

Imcivree’s approval in a type of obesity driven by brain injury could unlock an opportunity Wall Street analysts believe to ...

Obesity is increasing at an alarming rate throughout the world, particularly among children. Epidemiological and experimental data have suggested that suboptimal nutrition and growth during prenatal ...

Rhythm Pharma (RYTM) surges on IMCIVREE sales growth and TRANSCEND data ahead of the March 20 FDA PDUFA decision—see risks, ...